Richard Brudnick - 16 Feb 2022 Form 4 Insider Report for Codiak BioSciences, Inc.

Role: Officer title: Chief Business Officer and Head of Corporate Strategy
Signature: /s/ Yalonda Howze, Attorney-in-Fact for Richard Brudnick
Issuer symbol: N/A
Transactions as of: 16 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 18 Feb 2022, 15:05:57 UTC
Previous filing: 21 Jan 2022
Next filing: 08 Apr 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CDAKQ	Stock Option (Right to Buy)	Award	$0	+10,850		$0.000000	10,850	16 Feb 2022	Common Stock	10,850	$5.21	Direct	F1
transaction	CDAKQ	Restricted Stock Units	Award	$0	+16,275		$0.000000	16,275	16 Feb 2022	Common Stock	16,275		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of this option shall vest and become exercisable on February 16, 2023, with the remainder vesting in 12 equal quarterly installments thereafter.
F2	Each restricted stock unit represents a contingent right to receive one share of common stock.
F3	On February 16, 2022, the reporting person was granted 16,275 restricted stock units, vesting in four equal installments every six months beginning on the six month anniversary of the grant date.

Remarks:

Officer title: Chief Business Officer and Head of Corporate Strategy